HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinico-hematological evaluation of 57 patients undergoing antiaggregant treatment with indobufen].

Abstract
A long-term administration of Indobufen, 400 mg daily, was evaluated in 57 patients with cardiovascular diseases. Aggregation waves induced by ADP, collagen and epinephrine showed a significant and persistent inhibition of platelet function. Minor side effects were observed and in 6 patients the drug was withdrawn: 4 patients began to experience gastric troubles, 1 patient had positive occult test for blood, 1 patient developed an allergic rush. Clinical evaluation and platelet aggregation study before starting indobufen and during the follow up period seem to be useful in the evaluation of effectiveness, safety, compliance and suitable daily dose.
AuthorsA Andriani, G Mosiello, M G Chiappetta, G Gregori, P Rinaldi
JournalRecenti progressi in medicina (Recenti Prog Med) Vol. 81 Issue 1 Pg. 49-53 (Jan 1990) ISSN: 0034-1193 [Print] Italy
Vernacular TitleValutazione clinico-ematologica di 57 pazienti in trattamento antiaggregante con indobufene.
PMID2236828 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)
Chemical References
  • Isoindoles
  • Phenylbutyrates
  • Platelet Aggregation Inhibitors
  • indobufen
Topics
  • Cardiovascular Diseases (blood, drug therapy)
  • Female
  • Humans
  • Isoindoles
  • Male
  • Middle Aged
  • Phenylbutyrates (administration & dosage, adverse effects, therapeutic use)
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: